The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co in a patent dispute over its cancer drug Alimta with Neptune Generics LLC and Sandoz Inc.
(Reuters) – The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co in a patent dispute over its cancer drug Alimta with Neptune Generics LLC and Sandoz Inc.
Alimta, Lilly&rsquo-s top-selling oncology treatment, generated sales of $2.3 billion last year.
0 comments
Share
